Kyverna Therapeutics, Inc. (KYTX)
USD 3.79
(-9.55%)
USD 3.79
(-9.55%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | 7.02 Million | 5.65 Million |
| Cost of Revenue | 1.7 Million | 1.05 Million | 586 Thousand |
| Gross Profit | -1.7 Million | 5.97 Million | 5.07 Million |
| Operating Expenses | 62.4 Million | 36.4 Million | 32 Million |
| Selling, General and Administrative Expenses | 12.48 Million | 8 Million | 6.15 Million |
| Research and Development Expenses | 49.92 Million | 28.4 Million | 25.85 Million |
| Other Expenses | - | -9000.00 | -2000.00 |
| Cost and Expenses | 62.4 Million | 36.4 Million | 32 Million |
| Operating Income | -62.4 Million | -29.38 Million | -26.34 Million |
| Interest Expense | 187 Thousand | 65 Thousand | 3000.00 |
| Income Tax Expense | - | 56 Thousand | 1000.00 |
| Earnings before Tax | -60.36 Million | -28.89 Million | -26.35 Million |
| Net Income | -60.36 Million | -28.89 Million | -26.35 Million |
| Earnings Per Share Basic | -0.00 | -1.12 | -1.02 |
| Earnings Per Share Diluted | -0.00 | -1.12 | -1.02 |
| Weighted Average Shares Outstanding | 673.62 Million | 25.8 Million | 25.8 Million |
| Weighted Average Shares Outstanding (Diluted) | 673.62 Million | 25.8 Million | 25.8 Million |
| Gross Margin | - | 0.85 | 0.90 |
| EBIT Margin | - | -3.95 | -4.55 |
| Profit Margin | - | -4.11 | -4.66 |
| EBITDA | -58.47 Million | -27.77 Million | -25.76 Million |
| Earnings Before Tax Margin | - | -4.18 | -4.66 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 530 Thousand | 482 Thousand | 462 Thousand | 1.7 Million | 438 Thousand | 413 Thousand |
| Gross Profit | -530 Thousand | -482 Thousand | -462 Thousand | -1.7 Million | -438 Thousand | -413 Thousand |
| Operating Expenses | 32.9 Million | 29.35 Million | 21.37 Million | 62.4 Million | 15.84 Million | 12.88 Million |
| Selling, General and Administrative Expenses | 6.11 Million | 6.88 Million | 4.21 Million | - | 2.63 Million | 2.89 Million |
| Research and Development Expenses | 26.79 Million | 22.47 Million | 17.16 Million | - | 13.2 Million | 9.99 Million |
| Other Expenses | -23 Thousand | -26 Thousand | -32 Thousand | -55 Thousand | -13 Thousand | -7000.00 |
| Cost and Expenses | 33.43 Million | 29.35 Million | 21.37 Million | 62.4 Million | 16.28 Million | 13.3 Million |
| Operating Income | -33.43 Million | -29.35 Million | -21.37 Million | -62.4 Million | -16.28 Million | -13.3 Million |
| Interest Expense | 39 Thousand | 44 Thousand | 47 Thousand | 187 Thousand | 50 Thousand | 46 Thousand |
| Income Tax Expense | - | 18 Thousand | 15 Thousand | 132 Thousand | - | - |
| Earnings before Tax | -28.8 Million | -26.69 Million | -20.66 Million | -60.36 Million | -15.46 Million | -13.09 Million |
| Net Income | -28.8 Million | -26.69 Million | -20.66 Million | -60.36 Million | -15.46 Million | -13.09 Million |
| Earnings Per Share Basic | -0.67 | -1.12 | -0.48 | - | -0.36 | -0.30 |
| Earnings Per Share Diluted | -0.67 | -1.12 | -0.48 | - | -0.36 | -0.30 |
| Weighted Average Shares Outstanding | 43.14 Million | 23.75 Million | 43.11 Million | 40.82 Million | 43.11 Million | 43.11 Million |
| Weighted Average Shares Outstanding (Diluted) | 43.14 Million | 23.75 Million | 43.11 Million | 40.82 Million | 43.11 Million | 43.11 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -32.9 Million | -26.16 Million | -20.15 Million | - | -15.84 Million | -12.88 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
CARTRADE
MTS
AIA
277810
1742
AUTOIND